Quantitation of Limaprost, an Analogue of PGE1 in Human Plasma

Significance of the Topic

Quantitative determination of limaprost in human plasma is critical for its pharmacokinetic profiling and clinical monitoring. Achieving sub-pg/mL sensitivity while resolving endogenous interferences poses significant analytical challenges. A streamlined, high-throughput method enhances drug development efficiency and supports regulated bioanalysis.

Objectives and Study Overview

This study aimed to develop a simplified one-dimensional LC-MS/MS assay for limaprost quantitation by integrating differential mobility separation (DMS) on a QTRAP® 6500+ system. Key goals included reducing analysis time, lowering the limit of quantitation, and maintaining robust selectivity compared to existing two-dimensional LC-MS/MS methods.

Materials and Methods

Sample preparation followed a three-step solid-phase extraction of human plasma. Chromatography employed a Kinetex C18 column (2.1×50 mm, 1.7 µm) with a gradient of ammonium acetate (pH 4.5)/acetonitrile and a 15 min run at 0.3 mL/min. Mass spectrometric detection utilized multiple reaction monitoring (MRM) in negative-ion mode (m/z 379.2 > 299.3). A SelexION®+ DMS device applied a separation voltage and a compound-specific compensation voltage of –7.5 V to filter co-eluting species.

Used Instrumentation

• SCIEX QTRAP® 6500+ LC-MS/MS system
• SelexION®+ differential mobility separation device
• Shimadzu Prominence LC system
• Kinetex C18 column (Phenomenex Inc.)
• Analyst® 1.6.3 and MultiQuant™ 3.0 software

Main Results and Discussion

The developed assay achieved a lower limit of quantitation of 0.3 pg/mL, with excellent linearity from 0.3 to 15 pg/mL using 1/x weighting. Three quality control levels (0.6, 3, and 12 pg/mL) demonstrated precision with CVs below 2%. Integration of SelexION+ doubled ion transmission, suppressed isobaric/isomeric interferences, and reduced background noise, resulting in superior signal-to-noise ratios on a single-dimension LC method.

Benefits and Practical Applications

• Analysis time reduced over threefold (15 min vs. >50 min)
• Sub-pg/mL sensitivity supports pharmacokinetic studies
• Enhanced selectivity via orthogonal DMS separation
• Rapid installation/removal of DMS device without breaking vacuum
• High robustness and regulatory compliance for bioanalysis

Future Trends and Potential Applications

Advances in differential mobility spectrometry are expected to expand to other low-abundance biomolecules, enabling ultra-fast screening workflows. Integration with automated sample handling and machine-learning-guided optimization may further enhance throughput and method development. Broader adoption of DMS-enabled platforms could streamline regulated bioanalysis in clinical and industrial settings.

Conclusion

The one-dimensional LC-MS/MS assay combining a QTRAP 6500+ system with SelexION+ DMS offers a highly sensitive, selective, and efficient approach for limaprost quantitation in human plasma. It delivers significant improvements in speed, reproducibility, and ease of operation compared to traditional two-dimensional methods.

References

1. Komaba J, Masuda Y, Hashimoto Y, et al. Ultra sensitive determination of limaprost, a prostaglandin E1 analogue, in human plasma using online two-dimensional reversed-phase liquid chromatography–tandem mass spectrometry. J Chromatogr B. 2007;852:590–7.
2. Park YS, Park JH, Kim SH, et al. Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in healthy Korean volunteers. Clin Appl Thromb Hemost. 2010;16:326–33.